Verition Fund Management
LYEL icon

Verition Fund Management’s Lyell Immunopharma LYEL Stock Holding History

Verition Fund Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,750
Closed -$51.5K – 2541
2023
Q3 		$51.5K Buy
+1,750
New +$83.1K ﹤0.01% 2183

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Verition Fund Management's LYEL Position: Q4 2023 in Review

Verition Fund Management sold out of Lyell Immunopharma (LYEL) in Q4 2023, closing a stake of 1,750 shares — an estimated $51.5K sold.

Verition Fund Management first reported a position in LYEL in Q3 2023 and held it in 1 quarter. The position peaked at $51.5K in Q3 2023. 118 funds tracked by Wall St. Rank hold LYEL as of Q4 2023.

  • Verition Fund Management reported no remaining Lyell Immunopharma position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 1,750 Lyell Immunopharma shares in Q4 2023, an estimated $51.5K.
  • Verition Fund Management first reported a position in Lyell Immunopharma in Q3 2023 and held it in 1 quarter.
  • Verition Fund Management's Lyell Immunopharma position peaked at $51.5K in Q3 2023.
  • 118 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.